StockNews.AI
XGN
StockNews.AI
1 min

Exagen Inc. Reports Strong Q3 2025 Results

1. Exagen reported Q3 2025 revenue of $17.2 million, up 38% year-over-year. 2. Gross margin increased to 58.4%, reflecting improved efficiency in operations. 3. Net loss for Q3 2025 was $7.1 million, worse compared to $5 million in Q3 2024. 4. AVISE CTD test volume grew by 16% from Q3 2024, indicating strong demand. 5. The company reiterates full-year 2025 revenue guidance of $65 million to $70 million.

15m saved
Insight
Article

FAQ

Why Bullish?

Revenue growth and improved margins signal positive business trends. Such trends can boost investor confidence, exemplified by stock performance improvements after similar growth reports from comparable companies.

How important is it?

The notable revenue increase and improvement in operational efficiency directly suggest potential market optimism, significantly relevant for investors interested in Exagen's growth trajectory.

Why Short Term?

Recent performance metrics can quickly influence stock price volatility. Immediate investor sentiment will react to recent earnings calls and growth figures.

Related Companies

ILMNDGXLH
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,253)Net loss $(7,087) $(5,028) $(15,278) $(11,354)Adjusted EBITDA $(1,895) $(4,024) $(6,124) $(7,614)Cash and cash equivalents $35,652  $22,035  $35,652  $22,035 Trailing-twelve-month average selling price (ASP) $441  $404  $441  $404                   Q3 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $17.2 million, representing a 38% increase compared to the third quarter of 2024, or a 26% increase before the impact of one-time adjustments recorded in 2024.Grew AVISE CTD test volume 16% compared to the third quarter of 2024. Expanded AVISE CTD trailing twelve-month ASP to $441 per test, an increase of $37 per test over the third quarter of 2024. Ended the third quarter of 2025 with $35.7 million in cash and cash equivalents, up from $30.0 million in the second quarter of 2025.At the end of Q3, commercially launched seronegative RA markers for anti-PAD4, the latest enhancement to the AVISE CTD panel.    Presented six abstracts at the American College of Rheumatology Conference, including a plenary presentation related to the continued development of a lupus nephritis platform. 2025 Guidance  The company reiterates expected 2025 full-year revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025. Conference Call A conference call to review third quarter 2025 financial results and to provide a business update is scheduled for today, November 4, 2025, at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Additionally, a link to a live webcast of the call will be available in the Investor Relations section of Exagen's website at investors.exagen.com. Participants are asked to join a few minutes prior to the call to register for the event. A replay of the conference call will be available until November 18, 2025. Interested parties may access the replay by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13756599. A link to the replay of the webcast will also be available in the Investor Relations section of Exagen's website. Use of Non-GAAP Financial Measures (UNAUDITED) In addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure. Adjusted EBITDA excludes from net loss interest income (expense), income tax expense (benefit), depreciation and amortization expense, stock-based compensation expense, loss on extinguishment of debt, change in fair value of warrant liability, income taxes and other expenses or income that management believes are not representative of the company’s operations. Such items could have a significant impact on the calculation of GAAP net loss. Exagen uses adjusted EBITDA internally because the company believes these metrics provide useful supplemental information in assessing its operating performance reported in accordance with GAAP. Exagen believes adjusted EBITDA may enhance an evaluation of the operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses the company believes are not indicative of the ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes. This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with the financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that Exagen may exclude for purposes of these non-GAAP financial measures, and the company may in the future cease to exclude items that it has historically excluded for purposes of these non-GAAP financial measures. Likewise, Exagen may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by the company in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures. A reconciliation of net loss to non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release. About Exagen Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow Exagen on LinkedIn. Forward Looking Statements Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies, positioning, and ambitions; evaluations and judgments regarding financial results and the potential implications of those results, potential future financial and business performance, including any improvements to adjusted EBITDA, ASP, net loss and potential profitability; the potential utility and effectiveness of Exagen’s services and testing solutions; potential stockholder value and growth and full-year 2025 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; the potential effects of inflation and tariffs on Exagen’s margins; and changes in laws and regulations related to Exagen’s regulatory requirements. Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; and ability to obtain additional funding; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 5, 2025 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Ryan DouglasExagen Inc.ir@exagen.com 760.560.1525 Exagen Inc.Unaudited Condensed Statements of Operations(in thousands, except share and per share data)   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024   Revenue $17,244  $12,507  $49,944  $41,986 Cost of revenue  7,169   5,526   20,351   17,351 Gross profit  10,075   6,981   29,593   24,635 Operating expenses:        Selling, general and administrative expenses  11,445   10,163   34,191   31,169 Research and development expenses  1,730   1,481   4,497   3,719 Total operating expenses  13,175   11,644   38,688   34,888 Loss from operations  (3,100)  (4,663)  (9,095)  (10,253)Interest expense  (1,319)  (562)  (2,988)  (1,671)Loss on extinguishment of debt  —   —   (295)  — Change in fair value of warrant liability  (2,670)  —   (3,108)  — Interest income  3   197   246   570 Loss before income taxes  (7,086)  (5,028)  (15,240)  (11,354)Income tax expense  (1)  —   (38)  — Net loss $(7,087) $(5,028) $(15,278) $(11,354)Net loss per share, basic and diluted $(0.31) $(0.28) $(0.73) $(0.63)Weighted-average number of shares used to compute net loss per share, basic and diluted  22,940,412   18,254,937   20,878,373   18,127,549  Exagen Inc.Unaudited Condensed Balance Sheets(in thousands, except share and per share data)   September 30, 2025 December 31, 2024     Assets    Current assets:    Cash and cash equivalents $35,652  $22,036 Accounts receivable, net  11,092   7,835 Prepaid expenses and other current assets  5,845   6,584 Total current assets  52,589   36,455 Property and equipment, net  7,494   5,283 Operating lease right-of-use assets  1,685   2,401 Other assets  1,055   550 Total assets $62,823  $44,689 Liabilities and Stockholders' Equity    Current liabilities:    Accounts payable $3,559  $4,137 Accrued and other current liabilities  5,684   6,916 Deferred revenue  641   733 Finance lease liabilities, current  1,134   201 Operating lease liabilities, current  1,192   1,096 Borrowings, current  680   423 Total current liabilities  12,890   13,506 Borrowings, non-current, net of discounts and debt issuance costs  22,261   19,822 Finance lease liabilities, non-current  2,141   157 Operating lease liabilities, non-current  759   1,664 Warrant liability  6,634   — Total liabilities  44,685   35,149 Commitments and contingencies (Note 5)    Stockholders' equity:    Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September 31, 2025 and December 31, 2024  —   — Common stock, $0.001 par value; 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 22,510,313 and 17,640,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively  23   18 Additional paid-in capital  327,724   303,853 Accumulated deficit  (309,609)  (294,331)Total stockholders' equity  18,138   9,540 Total liabilities and stockholders' equity $62,823  $44,689  Exagen Inc.Reconciliation of Non-GAAP Financial Measures (UNAUDITED) The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding the company's use of non-GAAP financial measures.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(in thousands)  Adjusted EBITDA        Net loss $(7,087) $(5,028) $(15,278) $(11,354)Other (income) expense  (3)  (197)  (246)  (570)Interest expense  1,319   562   2,988   1,671 Loss on extinguishment of debt  —   —   295   — Change in fair value of warrant liability  2,670   —   3,108   — Income tax expense  1   —   38   — Depreciation and amortization expense  612   422   1,518   1,309 Stock-based compensation expense  593   217   1,453   1,330 Adjusted EBITDA (Non-GAAP) $(1,895) $(4,024) $(6,124) $(7,614)

Related News